SEC Steps Up To Halt More Hype Stocks
Investor RockieK - at Seeking Alpha - Fri Nov 21, 1:14PM CST
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 15.49 (+0.09), VSR: 3.62 (+0.12), TKMR: 11.71 (+0.46), NNVC: 1.56 (-0.04), INO: 7.46 (+0.19), CMRX: 46.90 (+1.08), APT: 2.18 (+0.02), HEB: 0.19 (unch), SRPT: 30.02 (+0.66), SMED: 6.65 (-0.10), PLX: 1.82 (+0.03), NLNK: 46.82 (+2.23), LAKE: 10.59 (+0.12), NSPH: 2.90 (+0.04)
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML - Tue Oct 21, 7:03AM CDT
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease ("EVD"
Business Wire - Tue Oct 21, 7:00AM CDT
Immunotech Laboratories, Inc. (OTC PINK: IMMB) ("Immunotech" or the "Company"
Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. Enters Into Negotiations With Uldic Investment Pvt. Ltd. For Market Development
Business Wire - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc.(the "Company"
Immunotech Laboratories, Inc. Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS and Hepatitis C Viruses in Macedonia and Serbia
Filing Services Canada XHTML - Tue Oct 07, 8:03AM CDT
Immunotech Laboratories, Inc. Announces Successful Completion of Phase I and Phase II Field Trials of the Company's Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
Business Wire - Thu Aug 28, 8:00AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment"